Drugmaker's new weight-loss jab combo causes patients to shed 23% of body weight in trial, BEATING tirzepatide alone

From the Newshound archive · first published 30 September 2026 · last updated 2 October 2026.

A Phase 2 trial of EloraTZP — Eli Lilly's combination of the amylin drug eloralintide and tirzepatide — showed a mean weight reduction of 23.3% over 48 weeks in adults with obesity and type 2 diabetes, comfortably outpacing tirzepatide alone. Patients on the highest dose lost around 54 pounds, compared with 34 pounds for those on tirzepatide alone. Blood-sugar control also improved more sharply, with A1C dropping 2.9 percentage points against 2.4 points on tirzepatide alone.

Tolerability remains a concern: as many as 27% of patients on the combination withdrew because of side effects, versus only 2.9% on tirzepatide alone.

Citi analysts told clients the combination's results are 'comparable to tirzepatide in patients without type 2 diabetes', a group that typically loses far more weight.

The mid-stage trial of 367 adults has not yet been published in a peer-reviewed journal, and Lilly presented the Phase 2 results at the EASD meeting in Milan.